# Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

> **NCT04357587** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** External beam radiation
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04357587
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-06
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-09-25
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04357587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04357587, "Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04357587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*